Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee

NACompletedINTERVENTIONAL
Enrollment

408

Participants

Timeline

Start Date

October 24, 2011

Primary Completion Date

March 27, 2013

Study Completion Date

March 27, 2013

Conditions
Osteoarthritis of the Knee
Interventions
DRUG

Meloxicam

7.5mg x2 once a day for 12 weeks

DRUG

Placebo

Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.

Trial Locations (25)

100029

China-Japan Friendship Hospital/Rheumatology Department, Beijing

100032

Peking Union Medical College Hospital, Beijing

100044

Li Zhanguo, Beijing

100053

Rheumatology and Immunology Department, Xuanwu Hospital Capital Medical University, Beijing

100730

Peking Union Medical College Hospital, Orthopaedics, Beijing

150001

Rheumatology Department, The first Affiliated Hospital of Harbin Medical University, Harbin

200001

Renji Hospital Shanghai Jiao Tong University School of Medicine, Shanghai

200003

Rheumatology and Immunology Department, Shanghai Changzheng Hospital, Shanghai

200032

Zhongshan Hospital Fudan University, Rheumatology Department, Shanghai

210029

Jiangsu Province Hospital, Nanjing

230001

Anhui Province Hospital, Hefei

250012

QiLu Hospital of Shandong University, Jinan

252000

Liaocheng People's Hospital/Orthopaedics, Liaocheng

266011

Department of Immunology and Rheumatology, Qingdao Municipal Hospital, Qingdao

Department of Immunology and Rheumatology,Qingdao Municipal Hospital, Qingdao

300052

Department of Infectious Diseases & Immunology, Tianjin Medical University General Hospital, Tianjin

430022

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

510630

The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou

515041

The First Affiliated Hospital of Shantou Medical Collage, Shantou

610041

Department of Orthopedics, West China Hospital of Sichuan University, Chengdu

610044

Department of Rheumatology and Immunology,West China Hospital of Sichuan University, Chengdu

610072

Department of Rheumatology and Immunology, Sichuan Provincial People's Hospital, Chengdu

Sichuan Provincial People's Hospital, Rheumatology, Chengdu

710032

Xijing Hospital, The Fourth Military Medical University, Xi’an

Unknown

Rheumatology Department, The First Hospital of China Medical University, Shenyang

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT01430559 - Effect Of Meloxicam Versus Placebo In Mainland Chinese Patients With Osteoarthritis Of The Knee | Biotech Hunter | Biotech Hunter